NASDAQ
VANI
Last Price
US $1.34
Valuation
Financial
Performance
Cash flow to debt coverage
Vivani Medical, Inc. cash flow to debt ratio of -128.98% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Vivani Medical, Inc.'s free cash flow has decreased 19.45% from $-21.34M last year to $-25.49M, signaling decreasing performance
Debt-to-equity ratio
Vivani Medical, Inc.'s debt to equity ratio is 0.96, which means that the company's assets are unhealthy financed, signaling financial risk.
Debt-to-equity trend
Vivani Medical, Inc.'s debt has decreased relative to shareholder equity from 1.10 last year to 0.96 today, signaling strengthened financials
Net debt to EBITDA
Vivani Medical, Inc. has negative EBITDA, making leverage ratio unreliable
Interest coverage
Interest expense is not separately reported in Vivani Medical, Inc.'s latest filing, so interest coverage cannot be calculated.
Profit margin growth
Vivani Medical, Inc. has insufficient data to evaluate this check.
Current ratio
Vivani Medical, Inc.'s short-term assets of $17.90M exceed its short-term liabilities of $6.60M
Return on assets
Vivani Medical, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Vivani Medical, Inc.'s return on equity of -264.04%, is lower than 15.00%, indicating bad performance
Earnings quality
Vivani Medical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Vivani Medical, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
Vivani Medical, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Vivani Medical, Inc. has negative free cash flow, indicating cash burn
Earnings growth
Vivani Medical, Inc.'s yearly earnings has decreased 13.30% since last year from $-23.49M to $-26.61M, signaling decreasing performance
Revenue growth
Vivani Medical, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Return on invested capital
ROIC -74.45% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Vivani Medical, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Vivani Medical, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance
Return on equity consistency
Vivani Medical, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
Vivani Medical, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Vivani Medical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
Vivani Medical, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Vivani Medical, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Vivani Medical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Vivani Medical, Inc. has a price-to-book ratio of 6.01x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Price-to-sales ratio (TTM)
Vivani Medical, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-191.05%
Return on equity
ROIC: -73.94%
Valuation History
-
Price to Earnings
EV/EBITDA: -4.3X
Cash flow
Profit margin
-19.43%
Cash flow
-21.15%
Fair Value
Market $1.34
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.